- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02258776
The Effect of Pomegranate on Aging and Inflammation of the Skin (PomSkin)
Clinical Trial to Determine the Efficacy of Pomegranate for Skin Inflammation and Aging
The purpose of this study is to determine the efficacy of pomegranate extract and pomegranate juice on skin inflammation and aging. The information gained from this study may lead to the development of a pomegranate product that can decrease the effects of aging, inflammation and harmful bacteria on the skin.
In this study, two pomegranate products (extract and juice) will be compared with a placebo, a study product that looks like pomegranate extract, but contains no active ingredients.
Study Overview
Status
Intervention / Treatment
Detailed Description
Pomegranate (Punica granatum L.) is grown commercially in the Near East, India, Spain, Israel and the United States (California) where it is of significant economic importance1. Pomegranate fruits and products, including juice, tea, wine and extracts are widely consumed and recognized for their health benefits. Pomegranate (Punica granatum L.) fruit possesses strong antioxidant, anti-inflammatory and antiproliferative properties. In recent years, most health advantages of pomegranate have been attributed to the presence of ellagitannins, mainly punicalagins and ellagic acid. Punicalagin is unique to pomegranate and is part of a family of ellagitannins. The ellagitannins are hydrolyzed to ellagic acid in the gut, and further metabolized by the colon microflora to form urolith A and B. Investigations using pure bacterial cultures have shown that pomegranate by-products and punicalagins significantly inhibited the growth of pathogenic Escherichia coli, Pseudomonas aeruginosa, clostridia and Staphylococcus aureus.
Oral feeding of pomegranate fruit extract to mice afforded protection to mouse skin against the adverse effects of ultraviolet-B (UVB) radiation by modulating UVB-induced signaling pathways.5 Hydroalcoholic extract based-ointment from pomegranate was reported improving wound healing in vivo. Pomegranate ellagitannins have been demonstrated to have antimicrobial activity. Punicalagin is unique to pomegranate and is part of a family of ellagitannins. The ellagitannins are hydrolyzed to ellagic acid in the gut, and further metabolized by the colon microflora to form urolith A and B. Investigations using pure bacterial cultures have shown that pomegranate by-products and punicalagins significantly inhibited the growth of pathogenic Escherichia coli, Pseudomonas aeruginosa, clostridia and Staphylococcus aureus.
Pomegranate Extract (POMx) is made from pomegranate fruit as a byproduct of pomegranate juice (PJ) production. A second pressing of the fruit liberates a complex mixture of hydrolysable polyphenolic compounds normally ingested with pomegranate juice, and these are purified by spray drying. POMx powder is encapsulated for oral administration, with each capsule containing 1,000 mg of pomegranate polyphenols. The present study will determine whether a pomegranate product (POMx or PJ) can decrease skin photoaging, inflammation and skin pathogenic bacteria.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Center for Human Nutrition
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 30-45 years or older, female and any racial/ethnic group
- Subjects must understand and sign the informed consent prior to participation
- Subjects must be in generally good health
- Subjects must be able and willing to comply with the requirements of the protocol.
Exclusion Criteria:
- Oral or topical retinoid use within twelve months of entry into the study
- Non-compliant subjects
- Taking any antibiotics or other medication or dietary supplements regularly
- Subjects with a significant medical history or concurrent condition that the investigator(s) feel is not safe for the study
- Subjects who cannot avoid excessive exposure to either natural or artificial sunlight.
- Allergic to pomegranate products
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pomegranate Extract
15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate extract on skin inflammation and aging.
Subjects will be asked to take Pomx 1/day for 12 weeks.
|
Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
|
Active Comparator: Pomegranate Juice
15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate juice on skin inflammation and aging.
Subjects will be asked to take Pomx 1/day for 12 weeks.
|
Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
|
Placebo Comparator: Placebo
15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of placebo on skin inflammation and aging.
Subjects will be asked to take Pomx 1/day for 12 weeks.
|
Placebo will be taken 1/day for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in inflammatory markers between pomegranate extract and pomegranate juice versus placebo.
Time Frame: Baseline and 12 weeks
|
Utilization of a two-sample t-test to compare the change in between the three groups
|
Baseline and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Linear mixed effects models to evaluate effect of treatment of time trends and demographic covariates
Time Frame: Baseline and 12 weeks
|
Correlation between outcomes measures (e.g. between acne lesion count and skin microbiota) with mixed effects models
|
Baseline and 12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zhaoping Li, M.D., Ph.D., UCLA Department of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PomSkin 14-001011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Photoaging, Inflammation and Skin Pathogenic Bacteria
-
Trophy SkinCitruslabsCompletedAcne | Wrinkle | Photoaging | Skin InflammationUnited States
-
Johns Hopkins UniversityAmorepacific CorporationWithdrawnSkin Aging | Photoaging of Skin
-
Acibadem UniversityUnknownPhotoaging of Skin | Chronological Aging of SkinTurkey
-
Derming SRLCompleted
-
Derming SRLCompleted
-
Advanced DermatologyCompletedSkin Aging | Photoaging of SkinUnited States
-
Makati Medical CenterA. Menarini Philippines, Inc.CompletedCutaneous PhotoagingPhilippines
-
RoseLab Skin Optics LaboratoryCompleted
-
Goldman, Butterwick, Fitzpatrick and GroffBausch Health Americas, Inc.Active, not recruiting
-
University of British ColumbiaCompleted
Clinical Trials on Pomegranate Extract
-
National Research Council, SpainHospital Universitario Reina Sofia de CordobaCompletedColorectal CancerSpain
-
Dalin Tzu Chi General HospitalCompletedHearing ImpairmentTaiwan
-
National Research Council, SpainUniversidad Católica San Antonio de Murcia; The Scientific and Technological...Completed
-
Alexandria UniversityNot yet recruiting
-
University of California, Los AngelesCompletedCardiovascular Diseases
-
Roll International CorporationUnknownProstate CancerUnited States
-
University of WashingtonCompletedInflammation | Cardiovascular Disease | End Stage Renal DiseaseUnited States
-
Sakarya UniversityRecruitingPremenstrual Syndrome | PomegranateTurkey
-
National Research Council, SpainHospital General Universitario Reina Sofía de MurciaCompleted
-
Roll International CorporationUnknownProstate CancerUnited States